SoftBank Robotics Group Makes Strategic Equity Investment in Avalon SteriTech

SoftBank Robotics Group Corp. (“SBRG”) today announced its strategic equity investment in Avalon SteriTech (“Avalon”), marks a great step forward in strengthening the companies’ collaboration since its joint venture was established in March 2021.

SoftBank Robotics Group notes upon the completion of the transaction, SBRG will own approximately 5% stake in Avalon’s disinfection business. Mr. Kenichi Yoshida, Chief Business Officer of SoftBank Robotics Corp, will take part in its board of directors to support the continuous growth of the company.

The transaction is subject to customary closing conditions and is expected to close by the end of April 2022.

Avalon and SBRG continue to see a strong market demand for robotic disinfection technologies and how they successfully raised the bar of cleaning and disinfection in combatting the ongoing COVID-19 pandemic. In doing so, the two companies strive to innovate smart-cleaning products and customized solutions in Hong Kong and beyond, leveraging Avalon’s strengths in biotechnology and healthcare, and SBRG’s expertise in AI, automation, and robotics.

Building on the success of Whiz Gambit, the 2-in-1 AI-powered cleaning and disinfection robotics solution launched under the joint venture, has successfully extended its footprints worldwide from Asia Pacific to EMEA, forging ahead toward Australia, the United Arab Emirates, and the United States. As the pandemic rages on, Whiz Gambit has been widely adopted by the public sector, hospitality, commercial, and healthcare industries, with over 100 of them serving the city’s extensive railway network in Hong Kong. Hence, Whiz Gambit was also a proud recipient of several international recognitions including the Innovation Honoree (Robotics) at the CES 2022 Innovation Awards.

“We are excited to deepen our strategic partnership with SoftBank Robotics Group, the worldwide leader in robotics solutions. Since last year, we have been working closely in accelerating the adoption of smart disinfection solutions and uplifting the public health standard that transcends conventional concepts of hygiene. The investment from SoftBank Robotics will bring tremendous momentum to our global market expansion, as we continue to work hand in hand with businesses, governments, and societies to safeguard the health and well-being of millions of people around the globe,” said Mr. Lewis Ho, Chief Executive Officer of Avalon SteriTech.

“SoftBank Robotics continues to identify innovative business approaches that enable us to stay at the forefront of providing robotics solutions. Equity investment is a capital efficient way for us to strengthen our participation in the ever-changing competitive robotics landscape. This opportunity to increase our stake and involvement will bolster our disinfection robots category. We are pleased to have found a like-minded partner like Avalon SteriTech, with their extensive knowledge in the biomedical sector, it will be integral to the success of this joint venture”, said Mr. Kenichi Yoshida, Chief Business Officer of SoftBank Robotics Group Corp.

Moving forward, the strategic partnership will focus on creative product development and strengthen business collaboration, from technologies and robotics innovation, business operations, and sales network establishment, setting foot in the dynamic global disinfection market. As the world sees the aviation industry’s recovery making its way, Avalon will be launching a new disinfection robot for mass transportation later this year. Currently, Avalon’s disinfection robot for the sector is serving Cathay Pacific Airways and MTR’s Airport Express for daily disinfection.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy